Effect of terfenadine on nasal, eustachian tube, and pulmonary function after provocative intranasal histamine challenge.
Previous studies have documented that intranasal histamine challenge results in nasal and eustachian tube obstruction (ETO) in human volunteers. The purpose of the present study was to assess the effect of pretreatment with terfenadine, a nonsedating antihistamine on the pathophysiologic consequences of intranasal histamine challenge. Fifteen subjects with allergic rhinitis were challenged intranasally with saline and increasing histamine doses (0.01, 0.1, 0.5, 1.0, 5.0, and 10.0 mg) before pretreatment (baseline) and after 1 week of pretreatment with terfenadine, 60 mg b.i.d., terfenadine, 120 mg b.i.d., and placebo. Nasal conductance as measured by posterior rhinomanometry showed a dose-dependent, monotonic decrease following sequential administration of the histamine solutions, but there were no apparent differences in the average responses among the four challenge sessions. The frequency of ETO after histamine challenge was decreased by pretreatment with both doses of terfenadine, although this was not significant. Histamine-induced sneezing and rhinorrhea, but not congestion, were significantly reduced by terfenadine pretreatment. There was no evidence of extension of the histamine effects to the lower airway. The results of the present study suggest that terfenadine, a nonsedating antihistamine, had a favorable effect on sneezing and rhinorrhea after provocative intranasal histamine challenge, but did not significantly attenuate the subjective or objective nasal and ET obstructive responses.
Skoner
D P
DP
Department of Pediatrics, School of Medicine, University of Pittsburgh, Pennsylvania.
Doyle
W J
WJ
Boehm
S
S
Fireman
P
P
D000281:Administration, Intranasal; D000284:Administration, Oral; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005064:Eustachian Tube / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006632:Histamine / Q000008:administration & dosage*; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009299:Nasal Provocation Tests; D009666:Nose / Q000187:drug effects / Q000502:physiology*; D012220:Rhinitis / Q000517:prevention & control; D016593:Terfenadine / Q000494:pharmacology* / Q000627:therapeutic use
D016593:Terfenadine; D006632:Histamine